The Lupus Susceptibility Gene Pbx1 Regulates the Balance between Follicular Helper T Cell and Regulatory T Cell Differentiation.
Seung-Chul ChoiTarun E HutchinsonAnton A TitovHoward R SeayShiwu LiTodd M BruskoByron P CrokerShahram Salek-ArdakaniLaurence MorelPublished in: Journal of immunology (Baltimore, Md. : 1950) (2016)
Pbx1 controls chromatin accessibility to a large number of genes and is entirely conserved between mice and humans. The Pbx1-d dominant-negative isoform is more frequent in CD4(+) T cells from lupus patients than from healthy controls. Pbx1-d is associated with the production of autoreactive T cells in mice carrying the Sle1a1 lupus-susceptibility locus. Transgenic (Tg) expression of Pbx1-d in CD4(+) T cells reproduced the phenotypes of Sle1a1 mice, with increased inflammatory functions of CD4(+) T cells and impaired Foxp3(+) regulatory T cell (Treg) homeostasis. Pbx1-d-Tg expression also expanded the number of follicular helper T cells (TFHs) in a cell-intrinsic and Ag-specific manner, which was enhanced in recall responses and resulted in Th1-biased Abs. Moreover, Pbx1-d-Tg CD4(+) T cells upregulated the expression of miR-10a, miR-21, and miR-155, which were implicated in Treg and follicular helper T cell homeostasis. Our results suggest that Pbx1-d impacts lupus development by regulating effector T cell differentiation and promoting TFHs at the expense of Tregs. In addition, our results identify Pbx1 as a novel regulator of CD4(+) T cell effector function.
Keyphrases
- systemic lupus erythematosus
- regulatory t cells
- disease activity
- poor prognosis
- long non coding rna
- transcription factor
- cell proliferation
- dendritic cells
- high fat diet induced
- long noncoding rna
- end stage renal disease
- genome wide
- rheumatoid arthritis
- chronic kidney disease
- oxidative stress
- newly diagnosed
- stem cells
- mesenchymal stem cells
- single cell
- dna methylation
- dna damage
- cell therapy
- peritoneal dialysis
- metabolic syndrome
- insulin resistance
- genome wide identification
- quantum dots
- patient reported
- type iii
- patient reported outcomes